Literature DB >> 27284640

Plasticity of a critical antigenic determinant in the West Nile virus NY99 envelope protein domain III.

Jessica A Plante1, Maricela Torres2, Claire Y-H Huang3, David W C Beasley4.   

Abstract

West Nile virus (WNV) is a mosquito-borne flavivirus that causes febrile illness, encephalitis, and occasionally death in humans. The envelope protein is the main component of the WNV virion surface, and domain III of the envelope protein (EIII) is both a putative receptor binding domain and a target of highly specific, potently neutralizing antibodies. Envelope E-332 (E-332) is known to have naturally occurring variation and to be a key determinant of neutralization for anti-EIII antibodies. A panel of viruses containing all possible amino acid substitutions at E-332 was constructed. E-332 was found to be highly tolerant of mutation, and almost all of these changes had large impacts on antigenicity of EIII but only limited effects on growth or virulence phenotypes.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Domain III; Envelope; Flavivirus; West nile virus

Mesh:

Substances:

Year:  2016        PMID: 27284640      PMCID: PMC4969113          DOI: 10.1016/j.virol.2016.05.024

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  57 in total

1.  Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein.

Authors:  David W C Beasley; Alan D T Barrett
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  A combination of naturally occurring mutations in North American West Nile virus nonstructural protein genes and in the 3' untranslated region alters virus phenotype.

Authors:  C Todd Davis; Sareen E Galbraith; Shuliu Zhang; Melissa C Whiteman; Li Li; Richard M Kinney; Alan D T Barrett
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

3.  Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor alphaVbeta3 integrin.

Authors:  Jason Wei-Ming Lee; Justin Jang-Hann Chu; Mah-Lee Ng
Journal:  J Biol Chem       Date:  2005-11-07       Impact factor: 5.157

4.  Substitutions at the putative receptor-binding site of an encephalitic flavivirus alter virulence and host cell tropism and reveal a role for glycosaminoglycans in entry.

Authors:  E Lee; M Lobigs
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

5.  Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice.

Authors:  Huafang Lai; Michael Engle; Anja Fuchs; Thomas Keller; Syd Johnson; Sergey Gorlatov; Michael S Diamond; Qiang Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-01       Impact factor: 11.205

6.  An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells.

Authors:  Jan-Jong Hung; Meng-Ti Hsieh; Ming-Jer Young; Chuan-Liang Kao; Chwan-Chuen King; Wen Chang
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

Review 7.  The long-term outcomes of human West Nile virus infection.

Authors:  James J Sejvar
Journal:  Clin Infect Dis       Date:  2007-05-02       Impact factor: 9.079

8.  Structural basis of West Nile virus neutralization by a therapeutic antibody.

Authors:  Grant E Nybakken; Theodore Oliphant; Syd Johnson; Stephen Burke; Michael S Diamond; Daved H Fremont
Journal:  Nature       Date:  2005-09-29       Impact factor: 49.962

9.  Dissection of antibody specificities induced by yellow fever vaccination.

Authors:  Oksana Vratskikh; Karin Stiasny; Jürgen Zlatkovic; Georgios Tsouchnikas; Johanna Jarmer; Urs Karrer; Michael Roggendorf; Hedwig Roggendorf; Regina Allwinn; Franz X Heinz
Journal:  PLoS Pathog       Date:  2013-06-20       Impact factor: 6.823

10.  Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus.

Authors:  Byron E Martina; Penelopie Koraka; Petra van den Doel; Geert van Amerongen; Guus F Rimmelzwaan; Albert D M E Osterhaus
Journal:  Vaccine       Date:  2007-11-20       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.